Key result
Homozygous carriers of both ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms had a markedly increased risk of heart failure (adjusted OR 8.6, p=0.005) and significantly lower LVEF.
Why the study?
Do ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms increase the risk of heart failure?
Case-Control (n=338)
Do ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms increase the risk of heart failure?
Odds Ratio: 8.6
p-value: p=0.005
The ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms act synergistically to significantly increase the risk of developing heart failure and are associated with worse left ventricular function.
These polymorphisms may flag high-risk patients for closer monitoring; hypothesis-generating and should not yet change practice or risk models.
BACKGROUND: The endothelin (ET) system plays a central role in the control of myocardial function and its pathophysiology. The aim of the present study was to explore whether genetic variations of ET-1 (G/T substitution that predicts an Lys/Asn change at codon 198) and its receptor ET(A) (T/C in exon 6, H323H) could predispose carriers to heart failure (HF). METHODS: Genotyping at these two loci was done in 122 patients with HF [echocardiographic left ventricular ejection fraction (LVEF) < or =40%] and 216 age-matched subjects without HF. Causes of HF included ischemic (n = 96) and idiopathic cardiomyopathies (n = 26). RESULTS: The ET-1 Lys198Asn was significantly associated with the occurrence of HF (p = 0.005). The risk of HF was independently increased among Asn/Asn in comparison to Lys carriers (OR = 3.2, p = 0.03). Moreover, homozygous carriers of both ET-1 and ET(A) variants showed a marked increase in the risk of HF (adjusted OR = 8.6, p = 0.005), displayed significantly lower LVEF (p = 0.002) and higher left ventricular end-diastolic (p = 0.03) and end-systolic diameters (p = 0.04; for Asn/Asn and TT vs. Lys and C carriers of the ET-1 and ET(A )polymorphisms, respectively). Furthermore, the extent of coronary artery disease (r = -0.62, p < 0.0001) and the Asn/Asn and TT double genotype (r = -0.30, p = 0.0001) were the only significant and independent predictors of LVEF by multivariate analysis. CONCLUSIONS: The ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms seem to act synergistically to increase the risk of HF.
No takes yet. Share an insight, caveat, or question.
Colombo et al. (2006) conducted a case-control in Heart failure (n=338). ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms vs. Lys and C carriers (non-homozygous carriers) was evaluated on Occurrence of heart failure (adjusted OR 8.6, p=0.005). Homozygous carriers of both ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms had a markedly increased risk of heart failure (adjusted OR 8.6, p=0.005) and significantly lower LVEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: